KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables: 2009-2024

Historic Receivables for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Dec 2024 value amounting to $104.7 million.

  • Acadia Pharmaceuticals' Receivables rose 26.34% to $139.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.5 million, marking a year-over-year increase of 12.84%. This contributed to the annual value of $104.7 million for FY2024, which is 2.29% up from last year.
  • As of FY2024, Acadia Pharmaceuticals' Receivables stood at $104.7 million, which was up 2.29% from $102.3 million recorded in FY2023.
  • Acadia Pharmaceuticals' Receivables' 5-year high stood at $104.7 million during FY2024, with a 5-year trough of $50.3 million in FY2020.
  • Its 3-year average for Receivables is $90.0 million, with a median of $102.3 million in 2023.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Receivables decreased by 3.46% in 2022, and later surged by 62.25% in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' Receivables (Yearly) stood at $50.3 million in 2020, then increased by 29.96% to $65.3 million in 2021, then declined by 3.46% to $63.1 million in 2022, then spiked by 62.25% to $102.3 million in 2023, then increased by 2.29% to $104.7 million in 2024.